Top Markets
#1 Velas Velas +480.91%
#2 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#3 Siren Siren +107.10%
#4 Venom Venom +47.47%
#5 Gigachad Gigachad +25.21%
#6 Ontology Ontology +20.20%
#7 Scor Scor +17.10%
#8 TRIA TRIA +16.34%
#9 Dacxi Dacxi +16.27%
#10 BabyBoomToken BabyBoomToken +13.98%
Coin of the day
Velas Velas
設定
言語
日本
通貨
USD
テーマ
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
株式のランク #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
株価
$0.0416118
時価総額
$12.78M
変化（1日）
1.72%
変化（1年）
-22.01%
国
AU
取引 Noxopharm Limited (NOX)

カテゴリー

Healthcare
Noxopharm Limited（NOX）のP/S比率
March 2026 時点のP/S比率 TTM: 11.26
Noxopharm Limited の最新の財務報告および株価によると、現在のP/S比率（TTM）は 11.26 です。2024 年末時点でのP/S比率は 8.04 でした。
Noxopharm Limited の P/S 比率の履歴（2016 ～ 2026）
各年末時点のP/S比率
年 P/S比率 変化
2026 (TTM) 11.26 101.04%
2025 5.60 -30.33%
2024 8.04 284.34%
2023 2.09 -80.01%
2022 10.46 -65.53%
2021 30.35 1,000.90%
2020 2.76 -81.58%
2019 14.96 -78.61%
2018 69.96 -68.70%
2017 223.50 0.00%
2016 0.00 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差 国
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.55 -68.45%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.90 -12.04%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 -52.01%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 -45.48%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.04 -72.96%
AU